Reproductive Aging, FSH, and Apolipoprotein Biology in Alzheimer’s Disease
Muhammad YA.. Preprints.org, 2026-10-19
Topic: Gut, metabolism and diet
Plain-language summary
Alzheimer’s disease (AD) affects women more than men, with risk increasing during and after the menopausal transition. Estrogen deficiency has long been a leading explanation for this sex difference, but emerging evidence suggests that follicle-stimulating hormone (FSH) may represent an additional, contributory endocrine factor. This narrative and mechanistic review integrates evidence on reproductive aging, AD pathobiology, and sex differences in AD, with particular emphasis on endocrine, metabolic, protein-clearance, inflammatory, and vascular mechanisms. PubMed and Google Scholar were searched for peer-reviewed human studies, animal models, and mechanistic investigations published through September 2026, prioritizing primary research and systematic reviews concerning FSH signaling, ApoE biology, and AD pathophysiology. Circulating FSH rises markedly across the menopausal transition and has been associated with cerebral amyloid burden in women, although the magnitude of this association is modest relative to established genetic risk factors such as APOE ε4 and causal directionality has not been established in humans. Preclinical studies further suggest that elevated FSH may influence pathways relevant to AD, including C/EBPβ–δ-secretase signaling, neuronal glucose metabolism, mitochondrial function, autophagic-lysosomal clearance, and apolipoprotein biology. Several steps within these proposed mechanisms, including the predominance of Gαi coupling by neuronal FSH receptors and any direct FSH action on microglia, remain incompletely established. Dysregulation across these interrelated systems may contribute to Aβ accumulation, tau pathology, impaired protein clearance, and chronic neuroinflammation, while reproductive aging is also associated with vascular and blood-brain barrier changes that may precede classical AD pathology. Taken together, current evidence supports a model in which sustained FSH elevation may act as one component of the broader biological changes accompanying reproductive aging that influence AD vulnerability. Further human and mechanistic studies are needed to determine the magnitude, cellular pathways, and therapeutic relevance of this contribution.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Muhammad, Y. A. (2026). Reproductive Aging, FSH, and Apolipoprotein Biology in Alzheimer’s Disease. Preprints.org. https://doi.org/10.20944/preprints202604.0104.v4
Vancouver
Muhammad YA. Reproductive Aging, FSH, and Apolipoprotein Biology in Alzheimer’s Disease. Preprints.org. 2026. doi:10.20944/preprints202604.0104.v4.
BibTeX
@article{muhammad2026-afc592dc,
author = {Muhammad, Y. A.},
title = {{Reproductive Aging, FSH, and Apolipoprotein Biology in Alzheimer’s Disease}},
journal = {Preprints.org},
year = {2026},
doi = {10.20944/preprints202604.0104.v4},
url = {https://doi.org/10.20944/preprints202604.0104.v4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Estrogen deficiency has long been a leading explanation for this sex difference, but emerging evidence suggests that follicle-stimulating hormone (FSH) may represent an additional, contributory endocrine factor.
- Circulating FSH rises markedly across the menopausal transition and has been associated with cerebral amyloid burden in women, although the magnitude of this association is modest relative to established genetic risk factors such as APOE ε4 and causal directionality has not been established in humans.
- Preclinical studies further suggest that elevated FSH may influence pathways relevant to AD, including C/EBPβ–δ-secretase signaling, neuronal glucose metabolism, mitochondrial function, autophagic-lysosomal clearance, and apolipoprotein biology.
- Dysregulation across these interrelated systems may contribute to Aβ accumulation, tau pathology, impaired protein clearance, and chronic neuroinflammation, while reproductive aging is also associated with vascular and blood-brain barrier changes that may precede classical AD pathology.
- Taken together, current evidence supports a model in which sustained FSH elevation may act as one component of the broader biological changes accompanying reproductive aging that influence AD vulnerability.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Preprints.org) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 13 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100. |
| Total | 21 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Genetics from nearby years
Also tagged “apoe2”
265 studies in the library carry the topic tag “apoe2”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.